1,721,073 research outputs found

    La favorita. Splendon più belle / [Donizetti], comp. ; O. Luppi, B ; Coristi della Scala [acc orch]. Don Carlo. Dormirò sol / [Verdi], comp ; Oreste Luppi, B [acc p]

    No full text
    Titre uniforme : Donizetti, Gaetano (1797-1848). Compositeur. [La favorite]. Extrait ; arr. (italien)Titre uniforme : Verdi, Giuseppe (1813-1901). Compositeur. [Don Carlos (1884)]. ExtraitComprend : La favorita / [Donizetti], comp. ; O. Luppi, B ; Coristi della Scala [acc orch] ; Don Carlo / [Verdi], comp ; Oreste Luppi, B [acc p]Contient une table des matière

    Simon Boccanegra. Il lacerato spirito / [Verdi], comp. Mefistofele. Ecco il mondo / [Boito], comp ; Oresto Luppi, B [acc p]

    No full text
    Titre uniforme : Verdi, Giuseppe (1813-1901). Compositeur. [Simon Boccanegra]. ExtraitTitre uniforme : Boito, Arrigo (1842-1918). Compositeur. [Mefistofele]. ExtraitComprend : Simon Boccanegra / [Verdi], comp ; Oresto Luppi, B [acc p] ; Mefistofele / [Boito], comp ; Oresto Luppi, B [acc p]Contient une table des matière

    Behavioral Biases and the Law

    No full text
    Empirical and experimental evidence shows that individuals exhibit behavioral biases in their decision-making processes that depart from the full rationality paradigm. This paper discusses the effectiveness of alternative debiasing strategies, designed to induce socially preferable outcomes. Following Jolls, C. and Sunstein, C.R. (2006). Debiasing through law. J. Leg. Stud. 35: 199-242, this paper examines legal strategies that aim at "debiasing through law", attempting to reduce or eliminate boundedly rational behavior. Alternatively, policymakers can implement "insulating"legal strategies that separate the outcome from the biased behavior, without attempting to eradicate behavioral biases from the decision-making process. This paper compares these strategies in many areas, such as tort law, consumer safety law, and property law

    Salvator Rosa. Di sposo... di padre / [Gomes], comp. Gli ugonotti. Dispersa sen vada : canzone ugonotta / Meyerbeer, comp ; Oresto Luppi, B (Marcello) [acc p]

    No full text
    Titre uniforme : Gomes, Carlos (1836-1896). Compositeur. [Salvator Rosa]. ExtraitTitre uniforme : Meyerbeer, Giacomo (1791-1864). Compositeur. [Les Huguenots]. Extrait ; arr (italien)Comprend : Salvator Rosa / [Gomes], comp ; Oresto Luppi, B (Marcello) [acc p] ; Gli ugonotti / Meyerbeer, comp ; Oresto Luppi, B (Marcello) [acc p]Contient une table des matière

    Development of microparticles for oral administration of the non-conventional radical scavenger IAC and testing in an inflammatory rat model.

    No full text
    Development of microparticles for oral administration of the non-conventional radical scavenger IAC and testing in an inflammatory rat model 1)Cirillo S.. 2)Paolini M.. 3)Vivarelli F.. 4)Passerini N.. 5)Albertini B.. 6)Di sabatino M. 7)Corace G.. 8)Luppi B.. 9)Canistro D.. University of Bologna The bis (1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) is an innovative nonconventional radical scavenger used with success in several disease models, such as inflammation, neurological disorders, hepatitis and diabetes. To date, the main limit for the drug use is represented by the intraperitoneal (i.p.) route of administration used in the pharmacological treatments. In order to develop a delivery system that allowed both oral administration and the therapeutic efficacy, Solid Lipid Microparticles (SLMs) containing a theoretical 18% w/w of IAC have been produced. Recently, three formulations (A, B, C) have been tested at different dosages in an inflammation and pain rat model. Inflammatory model was induced by the use of an intraplantar injection of 100ml/paw of Freund's complete adjuvant (FCA). Administered per os at different dosages, IAC B (60% stearic acid-20% Compritol® HD5 ATO) was the most efficient formulation in reducing oedema and alleviating pain, compared to the gold standard Paracetamol. Since the anti-diabetic effects of the i.p. formulation of IAC was already demonstrated in vivo, we are now investigating the therapeutic efficacy of the selected (B) oral IAC formulation (SLMs) in streptozotocin-nicotinamide diabetic mice
    corecore